LY3002813 for Early Alzheimer's Disease (TRAILBLAZER-ALZ)

What Is This Study About?

TRAILBLAZER-ALZ aims to evaluate the safety, tolerability, and efficacy of the investigational drug LY3002813 in early symptomatic Alzheimer's disease.

Do I Qualify To Participate in This Study?

Must have:

• Gradual and progressive change in memory function for 6 months or longer
• Mini-Mental State Examination score of 20 to 28 or a flortaucipir positron emission tomography (PET) scan within past 6 months that meets criteria
• Meet criteria for 18F flortaucipir and 18F florbetapir PET scans

Must NOT have:

• History of long QT syndrome
• Use of a stable dose of an acetylcholinesterase inhibitor, such as donepezil (Aricept), galantamine (Razadyne), and rivastigmine (Exelon), and/or memantine (Namenda) for less than 2 months before randomization
• Inability to undergo magnetic resonance imaging

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

 

Who Is the General Study Contact?

For more information about this study or study sites, visit the TRAILBLAZER-ALZ study website, email clinicaltrials.gov@lilly.com, or call 1-877-285-4559 or 1-317-615-4559 Monday-Friday 9 a.m. to 5 p.m. Eastern.

Where Is This Study Located?

Who Sponsors This Study?

Lead: Eli Lilly and Company

Source: ClinicalTrials.gov ID: NCT03367403